Month: April 2021

Release – CanAlaska Uranium (CVVUF)(CVV:CA) – CanAlaska Change to Board

Posted on by Admin


CanAlaska Change to Board
Victor Fern to go to new role with Cameco and Orano
CanAlaska address change

 

Vancouver, Canada, April 5, 2021 – CanAlaska Uranium Ltd.
(TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) (“CanAlaska” or the “Company”) reports that Victor Fern has resigned from the CanAlaska Board to pursue a new community role supporting Cameco and Orano’s operations in the Athabasca Basin. CanAlaska’s Management and Board of Directors wish Victor well in this new community role, and wishes to acknowledge the strong supporting role Victor has had with the direction of the Company’s activities since his appointment in 2008.

At the time of his appointment in March 2008 Mr Victor Fern was the immediate past Chief of the Fond du Lac Denesuline First Nation, at Fond du Lac, Saskatchewan. Mr Fern has been a longstanding member of the environmental monitoring committee for the Northern Athabasca area, and is involved with various private business interests in the Fond du Lac-Black Lake area. His extensive experience at uranium mining and milling operations in Northern Saskatchewan, and his 13 year tenure on the CanAlaska board makes him well suited to his new role as an advisor and educator in the community.

CanAlaska President, Peter Dasler, comments, “It has been a pleasure to work with Victor for the past 14 years, and to meet his friends and community. His new Community Liaison responsibilities for Cameco and Orano highlight how well regarded and knowledgeable is Victor. We can all learn a lot from each other, and I look forward to continuing our friendship and interactions in multiple matters into the future. Thank you Victor, best wishes from me and CanAlaska’s Board.”

Other News

 CanAlaska is moving to new offices in our current building. The new office address is Suite 580, 625 Howe Street, Vancouver, BC. V6C 2T6. This address will take effect May 1 2021.

About CanAlaska Uranium

 CanAlaska Uranium Ltd. (TSX-V: CVV; OTCQB: CVVUF; Frankfurt: DH7N) holds interests in approximately 214,000 hectares (530,000 acres) in Canada’s Athabasca Basin – the “Saudi Arabia of Uranium.” CanAlaska’s strategic holdings have attracted major international mining companies. CanAlaska is currently working with Cameco and Denison at two of the Company’s properties in the Eastern Athabasca Basin. CanAlaska is a project generator positioned for discovery success in the world’s richest uranium district. The Company also holds properties prospective for nickel, copper, gold and diamonds. For further information visit www.canalaska.com.

The qualified technical person for this news release is Dr Karl Schimann, P. Geo, CanAlaska director and VP Exploration.

 

On behalf of the Board of Directors

 

“Peter Dasler”

Peter Dasler, M.Sc., P.Geo.

President & CEO

CanAlaska Uranium Ltd.

 

Contacts:

 

Peter Dasler, President

Tel: +1.604.688.3211 x 138

Email: info@canalaska.com

 

Cory Belyk, COO

Tel: +1.604.688.3211 x 138

Email: cbelyk@canalaska.com

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  

 Forward-looking information

 All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.

Source: CanAlaska Uranium Ltd.

Release – electroCore Inc. (ECOR) – Announces Regulatory Approval in Canada

Posted on by Admin


electroCore, Inc. Announces Regulatory Approval in Canada

 

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that 
Health Canada has granted regulatory approval for the promotion and sale of the gammaCore Sapphire family of products in 
Canada for prevention and therapeutic treatment of migraine and cluster headache, as outlined in the registration application with 
Health Canada.

gammaCore Sapphire will be distributed in 
Canada by 
RSK Medical Inc., pursuant to an exclusive distribution agreement announced on 
January 26, 2021. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, including minimum purchase commitments. “Patients and clinicians in 
Canada have been waiting years for this novel migraine and cluster headache therapy. 
RSK Medical Inc. is delighted to bring another breakthrough medical device technology to the Canadian marketplace. We look forward to working towards provincial healthcare funding for this patient group” said  Scott Kadwell, President of 
RSK Medical Inc.

“Migraine Canada is pleased to learn that a new device to treat migraine and cluster headaches has been approved by 
Health Canada. Timely and equitable access to diverse and affordable treatment options and devices are essential for patients living with these painful and debilitating diseases” said Dr.  Elizabeth Leroux, president of the 
Canadian Headache Society and the founder and chair of Migraine Canada.

“We are pleased to achieve another significant regulatory milestone as we expand our global business,” said Iain Strickland, electroCore’s Vice President of European Operations. “We are looking forward to supporting the growth of our Canadian distribution partner, RSK Medical Inc.”

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About RSK Medical, Inc.

Headquartered in 
Ontario, 
RSK Medical Inc. brings a wealth of experience, knowledge and keen responsiveness as a medical device supplier and is dedicated to providing innovative and disruptive medical device technologies to the Canadian clinical and patient community.

For more information, visit www.rskmedical.com  

About Migraine Canada
Migraine 
Canada is an alliance of patients and health care providers working together to improve the lives of people living with migraine and other headache disorders in 
Canada, through awareness, support, education, advocacy and research

For more information, visit www.migrainecanada.org

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in 
the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the 
European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore contraindications include but are not limited to:

  • Patients with an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
  • Patients with a metallic device, such as a stent, bone plate or bone screw, implanted at or near the neck
  • Patients who are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

Safety and efficacy of gammaCore have not been evaluated in the following patients:

  • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
  • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
  • Pediatric patients (less than 12 years of age)
  • Pregnant women
  • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the business, operating or financial impact of such studies; the commercial potential of nVNS generally and gammaCore in particular in 
Canada and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
ecor@cg.capital

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
summer.diaz@electrocore.com

Release – Genprex (GNPX) – to Present at the 2021 Virtual Cell and Gene Meeting on the Mediterranean

Posted on by Admin


Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

AUSTIN, Texas — (April 5, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President and Chief Operating Officer, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean, which will take place virtually April 6-9, 2021.

Event: 2021 Virtual Cell & Gene Meeting on the Mediterranean

Date: The conference will take place virtually Tuesday, April 6  – Friday, April 9

Time: Company presentations will be available to view on-demand throughout the entirety of the conference

Registration Link: https://alliancerm.swoogo.com/meetingonthemed2021

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean is a four-day virtual conference featuring more than 80 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The meeting also includes more than 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.

Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Stringham at lstringham@alliancerm.org and interested media should contact Kaitlyn Dupont at kdupont@alliancerm.org.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. 

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
(877) 774-GNPX (4679) ext. #3
media@genprex.com

Release – Capstone Turbine (CPST) – CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets Virtual Road Show

Posted on by Admin


Capstone Turbine CEO To Discuss Recent Revenue Growth Trends At The Upcoming Noble Capital Markets’ Virtual Road Show

 

VAN NUYS, CA / ACCESSWIRE / April 1, 2021 / Capstone Turbine Corporation (NASDAQ:CPST), the world’s leading manufacturer of clean energy technology microturbine systems, today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for Tuesday, April 6, 2021.

The virtual road show will feature a corporate presentation from Capstone Turbine President and Chief Executive Officer Darren Jamison, followed by a question and answer session moderated by Noble Senior Research Analyst Michael Heim, highlighting questions submitted by the audience.

“I look forward to discussing our recent top line revenue growth with potential shareholders as we execute against our strategic Revenue Growth Strategy, which consists of a six-element initiative designed to drive top line annual revenue,” said Darren Jamison, President and Chief Executive Officer of Capstone Turbine.

“I expect that the new Biden administration will create positive momentum for green initiatives and companies like Capstone, as President Biden recently signed an executive order to rejoin the U.S. into the Paris climate accord, his first major action to tackle global warming. In addition, the President’s recently proposed infrastructure plan will most likely have a green building and sustainability element,” added Mr. Jamison.

The live broadcast of the virtual road show is scheduled for Tuesday, April 6, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here.

Noble’s research, as well as news and advanced market data on Capstone Turbine is available on Channelchek.

About Capstone Turbine Corporation
Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today’s multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

About Noble Capital Markets
Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports. www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

About Channelchek
Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC / FINRA registered broker-dealer since 1984. www.channelchek.com email: contact@channelchek.com

Cautionary Note Regarding Forward-Looking Statements
This release and the Company’s presentation and responses to questions at the Noble Capital Markets’ Virtual Road Show contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the generation of improvement in gross margin and expense absorption and other statements regarding expectations, beliefs, plans, intentions and strategies of the Company. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events, or for any other reason. “Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

SOURCE: Capstone Turbine Corporation

How Fast are People Cutting the Cable Cord?

Posted on by Admin

 


Cord-Cutters, Advertisers, and Market Disruption

 

Internet television, or streaming TV, reached a tipping point last year. Viewers had more time at home to review the alternatives to cable and perhaps less money to pay for the cable subscription. This is only part of the reason why a full 15 percent of U.S. cable TV consumers cut the cord amid the pandemic-imposed lifestyle in 2020.

The number of subscribers to more traditional TV is fading just as the use of telephone landline customers faded after cell phones were adopted. And the change is happening quickly. The growth of TV viewers connected via streaming services grew to 84 million U.S. households according to eMarketer, while report fewer than 78 million U.S. households maintained a cable subscription by January 2021. This is causing accelerated disruption in spending on advertising. And the trend is unlikely to reverse. According to new research by TradeDesk and YouGov, the number of additional viewers who expect to cut the cord and be cable-free during 2021 is 27% which is an accelerated pace from the large 15% migration in 2020.

Subscriber Cost

Price is one of the factors driving this disruptive shift, but with untethered accessibility, fine-tuned selection, and the inclusion of traditional broadcasters offering online access, consumers can now opt for premium content they can watch where they want and on-demand. There is no longer a distinct prime time for viewing or advertisers, only prime shows.

Marketers acknowledge the rise of CTV and, as important, the move from linear TV. But, there still may be a heavier weighting toward ad spending on traditional TV relative to how the desired audience actually consumes news, sports, and entertainment. According to the TradeDesk report (The CTV Tipping Point), data indicates budgets are not yet fully allocated to where the target audience is most likely to be found. They reported that this is most prevalent for brands trying to reach a young audience. These brands are likely missing opportunities to reach potential customers who are no longer linked via a cable box. Despite the less than nimble shift, TradeDesk reports 89 percent of marketers believe that CTV advertising is just as, or more effective as linear TV. Each Spring a TV ad buying extravaganza named Upfronts is held where TV ad buyers and sellers hammer out billions in marketing agreements. At the most recent Upfronts, a majority (59 percent) of linear TV ad buyers said they’re making fewer upfront commitments in 2021, as the advertising industry is realigning to put their products on the screens of the right people.  One significant finding in the TradeDesk report is marketers’ preference for CTV to build awareness of their brands. Forty-three percent identified CTV as the number one channel for brand storytelling in 2021. The next best for introducing a brand was social media (29 percent), and then linear TV (26 percent).

Sports Impact

Live sports broadcasting is a factor helping to shift traditional activity among both advertisers and consumers. Live sports had been a key selling point keeping consumers attached to linear television. This is important because access to watch live sporting events has often been cited as a primary reason consumers continue to keep their cable subscriptions. However, the pandemic may have altered this as many viewers went without many major sporting events in 2020. Since then, as sports slowly return to traditional channels, audiences haven’t been following suit.

 

 

Advertisements

Many have migrated to new ways of watching live sports, including streaming and social. As a result of these shifts, TV marketers are adjusting their creative approach to take advantage of the benefits of CTV, which differ from the norms of linear TV. This has caused brands to develop new types of creative ads tailored for separate audiences.  According to the TradeDesk report, Ads are getting shorter, given that, the viewing experience on CTV differs from its linear counterpart. Additionally, marketers are also using more animation to prepare in case adjustments need to be made after the initial production.

Take-Away

Almost 50 percent of those who already have or plan to cut the cable cord say their main reason is that cable is too expensive. They just don’t feel they’re getting enough value with the service.  At the same time, more and more people are attracted to streaming services because they prefer the viewing experience and on-demand, where and when they’re ready. At present, about half of TV viewers say they still subscribe to cable TV services. Demographically the transition is being driven by more than the under-35 years-of-age population, 20 percent of cable subscribers 55 and older said they plan to cut the cord too.  

Once the cord is severed, and viewers adapt to the new services, they aren’t likely to return. Almost 79 percent of people who stopped paying for cable or never had it say they are unlikely to retain the service.

For investors, this growing shift to streaming means there could be opportunities in companies that provide streaming and ancillary services. Also, media companies to review to make see if they are changing as the world requires the new technology. Outside of the media industry, brands not reaching their intended audience with advertising may suffer as that could be a big differentiator between one brand and another with a similar product offering.

Suggested Reading:

Seeking Alpha Paywall Causes Frustration

Small Cap Names in a Big Crypto Market



Is it Smart to Avoid Brokers that Sell Order Flow?

Who Benefits from the American Jobs Plan?

 

Sources:

https://pages.thetradedesk.com/rs/527-INM-364/images/TheCTVTippingPoint_WhitePaper_TTD_Jan2021.pdf

https://digiday.com/marketing/upfrontses-wtf-upfronts/

https://www.fastcompany.com/90444295/the-major-battle-of-the-2020-streaming-wars-will-be-over-ads

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Who Benefits from the American Jobs Plan?

Posted on by Admin

 


Industries that Could Benefit from the New “American Jobs Plan”

 

The $2 trillion American Jobs Plan proposed by the U.S. President to address a broad list of infrastructure projects was presented last week. The plan is structured to be financed over 15 years by jacking up taxes by 33.3% on corporations. If adopted, after first being considered, altered, and voted on by the legislative branch, investors can expect a substantial impact on the winners and losers from such a massive amount of money redirected from some companies and distributed selectively based on any final plan.

Taxes

As proposed, the non-Covid related plan with the stated purpose of helping workers has a price tag of $2 trillion over eight years. The designers anticipate raising corporate taxes to 28% from 21% and increasing taxes on business done outside the U.S. One main impact is raising the legal tax rate on business profits.

The increase in the statutory tax rate on domestic corporate income would be targeted at companies with business exposure within the U.S. that are paying close to 21% now. These are the businesses that led the economic boom after benefitting from the 2017 corporate tax cuts. The sectors that this will touch the most include financial firms, industrial companies, and many consumer-oriented firms with sales primarily in the U.S.

As far as business sectors with a high global presence, and therefore at targeted for higher taxes on foreign profits, technology can be expected to experience higher tax burdens. The Health Care sector, primarily international drug, and device manufacturers have been major beneficiaries of low foreign profit taxes; this would be unwound under the present plan.

Spending

Sectors that would benefit from direct government spending if the plan is enacted are transportation and infrastructure. There is a carve-out of $447 billion in transportation infrastructure to repair highways, rebuild bridges, upgrade ports, airports, and transit systems. There is an additional $111 billion for drinking water-related infrastructure. Broadband internet would benefit from a $100 billion allocation for improving the reach of communication systems. Power generation, including “clean energy” and electric grid improvements, would receive $100 billion as currently proposed.

 

 

There is $300 billion tagged for revitalizing and strengthening the manufacturing supply chain, $180 billion for government-led advances in “critical” technology. More directly impacting consumers, the President’s proposal would spend $174 billion to further electric vehicles and $213 billion for “green” and “affordable” homes.

The increased taxes on companies would be funneled to traditional infrastructure investment, including industrial and materials companies, while the redirected wealth to environmental issues should increase government-led spending to renewable energy companies. Mining and other natural resource firms should benefit from the substantial material requirements for the movement toward more diverse energy sources, electric vehicles, and efficient homes.

Utilities stand to benefit from increased investment in water and cleaner energy infrastructure. Many communication services and technology firms will likely benefit from broadband improvement spending.

Take-Away

Channelchek can provide readers with research, analytics, news, and statistics on hundreds of small and microcap companies in the sectors mentioned above. Small companies that could potentially benefit from increased spending in; Basic Materials, Communication, Government-funded dredging, Forest Products, Transportation, and Technology, can be found starting here.

The legislative process is fluid, and the spending and tax plans could change in the coming months. Keep in touch with us for updates as Washington moves closer to a final plan.

 

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading:

How Much is a Trillion?

Are Inflation and Interest Rates Expected to Rise?




Managing Investment Portfolio Risk

Stimulus Checks, Taxes, and Investments


Stay up to date. Follow us:

           


Stay up to date. Follow us:

Was There Ever a Market Crash on Good Friday?

Posted on by Admin

 


The Real Reason the NYSE is Closed Good Friday

 

Three times a year, the NYSE’s holiday schedule differs from the U.S. Federal Government. Federal office closings usually dictate bank holidays as well. This happens on Columbus Day and Veterans Day; on these days, banks and the Federal Government are closed, the stock exchanges are open. Only on Good Friday is the market closed as Federal workers and bank employees have a regular workday.  Interestingly, the Friday before Easter is the only non-federal holiday among the exchange’s nine annual holidays. Traders, stock market employees, and others associated with transacting for U.S. equity markets can keep their work computers off, receive USPS mail, run to the bank, and even chat by phone with the IRS.

Why This One Particular Day?

Wall Street is full of superstitions, sayings, and stories with varying degrees of truthiness. The granddaddy of exchanges, the New York Stock Exchange, has been closed the Friday before Easter for over 150 years. There have been three exceptions (1898, 1906, and 1907), and during these years it stayed open that Friday. There is an often-heard tale that has circulated, referring to this day as “Black Friday.” As this fake news story goes, the NYSE had once opened its doors on a Good Friday, which occurs on the holiest week of the year for Christians, and the stock market had a terrible crash. This “bad karma” caused those governing the NYSE to vow to never again allow trading on the exchange on Good Friday.

There is no record of anything that would fit the above narrative. Plus, it begs the question, “why isn’t the market closed for superstitious reasons on other days of horrific selloffs?” Maybe March 23rd would be a wise day for those running the exchanges to consider guarding against the first week of Spring selloff in 2020.

Why there is no record? Because it never happened. Apparently, the story isn’t even Snopes-worthy because the only entries related to Good Friday or Black Friday respond to questions about Thanksgiving and resurrection, not market selloffs.

 

 

But I did find a story from what I deem to be a credible source or at least a wise codger that is believable on this question.  Art Cashin, the recognizable NYSE floor trader for UBS, slapped down this myth in his daily emailed newsletter back in 2011. In short, he wrote, “it never happened.”

Text From Art Cashin’s 2011 UBS Newsletter

“In the over five decades that I’ve been in Wall Street, each
Easter season sees the re-blooming of an old — and erroneous — myth.

“That myth contends that the NYSE opened on a Good Friday
and the terrible Black Friday crash occurred. Thus, chastened and shaken, the
Governors vowed never to open on a Good Friday again. It never happened.

“Thanks to the nice folks in the NYSE archives we were able
to establish a few facts. Records clearly show the NYSE closed on Good Friday
as far back as 1864. Before 1864 records on the subject are a bit harder to
find but there is high likelihood that the Exchange closed on Good Friday all
the way back to 1793. (It was founded on May 17th, 1792 so Good Friday would
have already passed that year.)

“There was a famous and terrible Black Friday crash in Wall
Street but it was primarily in the gold market. It came about when the ‘corner’
on gold that
Jay Gould and Jim Fisk had constructed (with
some help from President Grant’s brother-in-law), collapsed. That occurred on
September 24th, 1869, a little late in the year for Good Friday. You will also
note from the search of the records that the NYSE was closing on Good Friday at
least five years earlier and probably, much, much longer.

“Lastly, for some unexplained reason, the NYSE stayed open
on three Good Fridays. On April 8, 1898, the Dow closed down a half point.
That’s hardly a crash. On the other two, April 13th, 1906 (a Friday the 13th)
and March 29th, 1907, the Dow actually rose.”

“I hope that puts the myth to bed.”

Two Last Points

  • Of the three years the market stayed open on Good Friday, two closed higher than they opened, and one (1898) closed lower.
  • If you’re off today or missing the excitement of trading, enjoy your long weekend, the market will be there for you on Monday.

Paul Hoffman

Managing Director, Channelchek


Suggested Reading:

Long Term Retirement Money and Fledgling Companies

How Good are Experts at Predicting the Market?



An Opportunity to Ditch Chemotherapy and Still Treat Cancer

PSCs Can Function Like Embryonic Stem Cells

 

Sources:

Stock Market Legend Art Cashin

NYSE Holidays and Trading Hours

NYSE Historical Data

Photo: Art Cashin, NYSE

Stay up to date. Follow us:

           


Stay up to date. Follow us:

QuickChek – April 1, 2021

Posted on by Admin



Golden Predator Submits Brewery Creek License Renewal Applications

Golden Predator Mining announced that the Company has submitted its Water Use License and Quartz Mining License renewal applications for its 100%-owned Brewery Creek mine project

Research, News & Market Data on Golden Predator Mining

Watch recent presentation from NobleCon17



Bunker Hill Files 10-KT Transition Report for the Six Months Ended December 31, 2020

Bunker Hill Mining announced that it has filed a Form 10-KT transition report for the six months ended December 31, 2020, consistent with the change in its fiscal year end as announced on February 12, 2021

News & Market Data on Bunker Hill Mining



Onconova Therapeutics Announces Enrollment In Second Cohort Of Phase 1 Study With ON 123300 In China

Bunker Hill Mining announced that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in China

Research, News & Market Data on Bunker Hill Mining

Watch recent presentation from NobleCon17

Stay up to date. Follow us:

Release – Golden Predator Mining (NTGSF)(GPY:CA) – Submits Brewery Creek License Renewal Applications

Posted on by Admin


Golden Predator Submits Brewery Creek License Renewal Applications

 

Vancouver, BC, April 1, 2021:
Golden Predator Mining Corp. (TSX.V:GPY, OTCQX:NTGSF) (the “Company” or “Golden Predator”) advises the Company has submitted its Water Use License
(WUL) and Quartz Mining License (QML) renewal applications for its 100%-owned Brewery Creek mine project
located approximately 55 km by paved and gravel road from Dawson City, Yukon.
The Company looks forward to working with Tr’ondëk Hwëch’in, the Yukon
Department of Energy, Mines and Resources and the Yukon Water Board to advance
the renewal applications.  

The Brewery Creek Mine is a brownfields heap leach gold mine that was operated by Viceroy Minerals Corporation from 1996 to 2002. Important infrastructure remains in place allowing for a timely restart schedule.

Brewery Creek currently holds valid Quartz Mining and Water Use Licenses, which expire December 31, 2021. The Company has submitted renewal applications on existing terms and conditions for 10-year extensions to the Quartz Mining License (QML) Water Use License (WUL). Golden Predator is currently working on a document to meet Yukon Environmental Socioeconomic Assessment Act (YESAA) requirements and expects to submit the project plan in early Q3 2021.

Brewery Creek Mine Work Plan

A Feasibility Study (FS) is being conducted by Kappes Cassiday & Associates of Reno, Nevada which will include a multi-year mine plan for the advancement of the Brewery Creek project.   The FS will include an inventory of the mineralized material remaining on the heap and mine planning (completed by Tetra Tech Inc of Golden, Colorado) for the resumption of the mining of material from leachable resources contained within the licensed area and reported in the Company’s Mineral Resource Estimate.  The FS will include all the key parameters involved in reconstructing or adding necessary infrastructure including a crushing facility, the Adsorption-Desorption-Recovery (“ADR”) plant, mine schedule, operating and capital cost estimates, and economic cash flow model sufficiently detailed to move directly into procurement, development and construction if economically warranted. Any production decisions would be dependent on the outcome of a study demonstrating positive technical and economic viability.

Golden Predator Mining Corp – Viva Gold  Corp. (TSX.V: VAU; OTCQB: VAUCF) (“Viva Gold“)

The Company previously announced (March 3, 2021)  it has entered into a definitive arrangement agreement whereby Golden Predator will acquire all of the outstanding securities of Viva Gold by way of a plan of arrangement under the Business Corporations Act (British Columbia). The proposed Arrangement brings together proven mine building expertise, jurisdictional diversification and two advanced stage gold development projects as the two company’s merge their Nevada and Yukon assets and management to position the company as an emerging junior gold producer.

The technical content of this news release has been reviewed and approved by Michael Maslowski CPG, a Qualified Person as defined by National Instrument 43-101 and a consultant to the Company.

About Golden Predator Mining Corp.

Golden Predator is advancing the past-producing Brewery Creek Mine towards a timely resumption of mining activities in Canada’s Yukon. The project has established resources grading over 1.0 g/t Gold and both a technical report and Bankable Feasibility Study underway to define the economics of a restart of heap leach operations at the Brewery Creek Mine. The 180 km2 brownfield property is located 55 km by road from Dawson City, Yukon and operates under a Socio-Economic Accord with the Tr’ondëk Hwëch’in First Nation.  The Company also holds the Marg Project, with a 43-101 compliant resource, the Gold Dome Project and Grew Creek Project. For additional information on Golden Predator and the Brewery Creek Mine, please visit our website: www.goldenpredator.com.

For additional information:
Janet Lee-Sheriff
Chief Executive Officer
(604) 260-8435
info@goldenpredator.com

www.goldenpredator.com

Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term is defined
in policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release. No stock exchange, securities commission
or other regulatory authority has approved or disapproved the information
contained herein. This press release contains forward-looking information that
involve various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation statements based on
current expectations that the Brewery Creek will advance to an early production
decision, or the extent of any additional mineral resource that could result
from incorporating 2019 exploration drilling.  Actual results and future
events could differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are based on
estimates and opinions of management on the dates they are made and are
expressly qualified in their entirety by this notice. Except as required by
law, the Company assumes no obligation to update forward-looking information
should circumstances or management’s estimates or opinions change.

Differences Between Value and Growth

Posted on by Admin

 


Takeaways from the Ups and Downs of March

 

March came to an end, and many wounds from a rough year that followed a big fall of the various stock indices March 2020 have healed beyond the expectations held by most at this time last year. Focusing on last month (March 2021), the Nasdaq and the Russell 2000 (Small Caps) were up modestly, while the S&P 500 and the Dow Jones achieved outsized gains. One big takeaway from March 2020 is optimism among investors who feel they’re beginning to see the light at the end of the tunnel toward normalcy.

Reasons for the optimism are abundant, vaccinations are ramping up globally, travel is escalating toward more normal levels, and the latest release from the U.S. Department of Labor indicates that jobless claims have decreased to a 12-month low. It doesn’t require rose-colored-glasses to see where the overall economy has been headed with this cocktail of good news nor why the markets have been a leading positive indicator for the past year. Big money managers, as well as small investors, have been rotating out of the high-flyer tech stocks of last year and rebalancing their portfolios in anticipation of a roaring recovery.

 

Data as of March 31, 2021, 2 pm EDT

The back-to-normal expectations echoed among key opinion leaders, experts, and analysts within the finance community seem to be understood by those that actually put money to work in the stock market. Rebalancing of portfolios can be surmised from the graph above as industrial stocks lead (INDU) and the tech-heavy Nasdaq 100 (CCMP) has come to a crawl.  The numbers don’t lie, and, in this case, it is clear where the money managers are allocating. Value stocks have a reputation of supporting a strong and consistent portfolio, while growth is a riskier and more volatile option, but can reward owners willing to hold higher volatility.

During the past year, investors had been pouring their resources into growth portfolios as part of a global chain of events that aroused the need for technology, software, and various disruptive innovations. However, with the worldwide vaccine rollout and improvements in the economic outlook, portfolios are retreating some (mostly) to value. Let’s look at a brief breakdown of the Value, vs. Growth, vs. Large Cap during the first quarter of 2021.

 

Data as of March 31, 2021, 2 pm EDT

The rebalancing from growth to value started to reach a peak early in March as seen in the graph above. One thing that stands out from the current perception is that the small cap value stocks have outperformed large cap growth and large cap value. Both large and small cap value baskets have been enjoying solid performance above overall growth stocks since January 1.

Santiago Diaz

Associate Writer – Channelchek

More To Discover:

What Will the Stock Market do in the Spring?

What Stocks do You Buy When the Dollar Goes Down?



Managing Investment Portfolio Risk

IRA Investments and Small Cap Stocks

Sources:

U.S. Department of Labor

Koyfin.com

U.S. Transportation Security Administration

 

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Release – Onconova Therapeutics (ONTX) – Announces Enrollment In Second Cohort Of Phase 1 Study With ON 123300 In China

Posted on by Admin


Onconova Therapeutics Announces Enrollment In Second Cohort Of Phase 1 Study With ON 123300 In China

 

Corporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group

NEWTOWN, Pa., April 01, 2021 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China.

The HanX trial has enrolled six patients to date in two cohorts and may continue to enroll patients with advanced relapsed/refractory cancer at increasing doses with three to six patients per dose until the recommended Phase 2 dose is identified.   To date, patients have been dosed at the 40 mg and 80 mg dosage levels. HanX recently opened a third site, in Shanghai, for the conduct of the study.

“We are encouraged that the HanX Phase 1 study is proceeding as planned, and look forward to the identification of a recommended Phase 2 dose to move into later-stage trials. The third cohort in this trial with 120 mg of ON 123300 is expected to begin enrollment next; depending on the incidence of dose limiting toxicities, if any, at the 80 mg cohort,” said Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova Therapeutics. “The HanX study trial design calls for dosing on days 1-21 of each 28-day cycle, compared with our planned Phase 1 study in the U.S. that will assess the safety, tolerability and pharmacokinetics of ON 123300 administered orally as monotherapy at increasing doses starting at 40 mg daily for continuous 28-day cycles. We are preparing to begin our U.S. study in the second quarter of 2021.”

“ON 123300 is a multi-kinase inhibitor in addition to targeting CDK 4/6, which we believe presents an innovative approach to treating advanced cancers including HR+ HER2- metastatic breast cancer that is, or has become, resistant to commercial CDK 4/6 inhibitors. Beyond metastatic breast cancer, we believe ON 123300 may present an innovative approach to treating other cancers including mantle cell lymphoma, multiple myeloma, advanced colorectal cancer, hepatocellular carcinoma and inoperable glioblastoma,” concluded Dr. Fruchtman.

In December 2017, Onconova entered into an agreement with HanX Biopharmaceuticals for the development, registration, and commercialization of ON 123300 in Greater China. The agreement included a licensing fee, future potential milestone payments, and royalties on sales. Onconova retains rights to ON 123300 in the rest of the world outside of Greater China.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is planned to begin a dose-escalation and expansion Phase 1 trial in the U.S. in 2Q21, and a dose-escalation and expansion Phase 1 trial is currently underway in China.

Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, Onconova continues to conduct preclinical work investigating rigosertib in COVID-19.

For more information, please visit www.onconova.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the registered direct offering, its patents and clinical development plans including patient enrollment timelines and indications for its product candidates. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova’s clinical trials and regulatory agency and institutional review board approvals of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, Onconova’s collaborations, market conditions and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

Source: Onconova Therapeutics

Release – Bunker Hill Mining (BHLL)(BNKR:CA) – Files 10-KT Transition Report for the Six Months Ended December 31 2020

Posted on by Admin


Bunker Hill Files 10-KT Transition Report for the Six Months Ended December 31, 2020

 

TORONTO, March 31, 2021 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (CSE: BNKR) (“Bunker Hill” or the “Company) reports that it has filed a Form 10-KT transition report for the six months ended December 31, 2020, consistent with the change in its fiscal year end as announced on February 12, 2021. The report includes the Company’s audited financial statements for the six months ended December 31, 2020, management’s discussion and analysis, and other disclosure including all material events since the change in the Company’s management team approximately one year ago.
 

Sam Ash, CEO of Bunker Hill, stated: “As we look back on our first full year of Bunker Hill under new management, we are proud of the significant milestones that we have accomplished for our investors and stakeholders, including establishing and upgrading our resource, making a meaningfully positive impact on the environment and our community, and making significant strides to re-starting the mine. We look forward to realizing our near-term catalysts, most notably publishing our PEA”.

Key achievements over the last 12 months are summarized in the table below:

NEW

MANAGEMENT

TEAM
  • Richard Williams appointed Executive Chairman in March 2020; previously Barrick’s COO
  • Sam Ash appointed President & CEO in April 2020; previously Barrick’s GM of Lumwana Copper Mine
  • Brad Barnett appointed VP Sustainability in April 2020; previously Barrick’s Head of Closure & Rehab
  • David Wiens appointed CFO & Corporate Secretary on January 12, 2021; previously SSR Mining
ESG

DRIVEN

VISION
  • Water management program launched in September 2020; commissioned pre-treatment plant designed to significantly improve quality of Mine discharge water; immediate results
  • Engagement with community and local stakeholders
  • Pam Saxton appointed Independent Director in October 2020; Chair of Audit Committee
  • Cassandra Joseph appointed Independent Director in November 2020; Chair of Governance Committee
ADVANCED

POTENTIAL

MINE RESTART
  • Renegotiated Lease and Option Agreement in November 2020, lowering cash purchase price to $3.4M
  • Repaired several thousand feet of Russell Tunnel, providing early access to UTZ Zone, Quill and Newgard Zones, with plans to extend further access
  • Launched PEA assessing rapid production restart; results expected early Q2-2021
EXPLORATION

SUCCESS
  • Digitized 95 years of historical data to develop proprietary geological model and prioritize targets
  • Achieved maiden mineral resource estimate announced in September 2020
  • Announced upgraded mineral resource estimate in March 2021
  • Confirmed high grade silver mineralization results in several areas through drilling and chip sampling

For further information please see the Company’s Form 10-KT filed on SEDAR at www.sedar.com and EDGAR www.sec.gov under the Company’s profile.

UPCOMING EVENTS

Adelaide Capital Idaho Conference
April 8, 2021 @ 12:00pm ET – 4:00pm ET
Join Us: REGISTER NOW

World Gold Forum
April 13-15, 2021
https://www.worldgoldforum.com/

HC Wainwright Mining Conference
April 19-20, 2021
Join Us: REGISTER NOW

121 Mining Investment Americas
April 27-29, 2021
https://www.weare121.com/121mininginvestment-new-york/

QUALIFIED PERSON

Mr. Scott E. Wilson, CPG, President of Resource Development Associates Inc. and a consultant to the Company, is an independent qualified person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects and is acting as the qualified person for the Company. He has reviewed and approved the technical information summarized in this news release.

ABOUT BUNKER HILL MINING CORP.

Under new Idaho-based leadership, Bunker Hill Mining Corp. intends to sustainably restart and develop the Bunker Hill Mine as the first step in consolidating a portfolio of North American precious-metal assets with a focus on silver. Information about the Company is available on its website, www.bunkerhillmining.com , or under the Company’s profile on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .

For additional information contact:

Sam Ash, President and Chief Executive Officer

+1 208 786 6999

sa@bunkerhillmining.com

CAUTIONARY STATEMENTS

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase ‘forward-looking information’ in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations. Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by terminology such as “may”, “will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “projects”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts.

Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The key risks and uncertainties include, but are not limited to: local and global political and economic conditions; governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, government ownership requirements, changes in environmental, tax and other laws or regulations and the interpretation thereof; developments with respect to the coronavirus disease 2019 (“COVID-19”) pandemic, including the duration, severity and scope of the pandemic and potential impacts on mining operations; and other risk factors detailed from time to time in the Company’s reports filed on SEDAR and EDGAR.

Forward-looking information and statements in this news release include statements concerning, among other things: the Company’s plans to extend further access to the UTZ Zone, Quill and Newgard Zones; the timing for publishing the PEA aimed at assessing the mine’s rapid restart potential; and the Company’s intentions regarding its objectives, goals or future plans and statements. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to: the ability to predict and counteract the effects of COVID-19 on the business of the Company, including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restriction on labor and international travel and supply chains; failure to identify mineral resources; failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; changes in equity markets; uncertainties relating to the availability and costs of financing needed in the future; the inability of the Company to budget and manage its liquidity in light of the failure to obtain additional financing, including the ability of the Company to complete the payments pursuant to the terms of the agreement to acquire the Bunker Hill Mine Complex; inflation; changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; capital, operating and reclamation costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in the Company’s public documents filed on SEDAR and EDGAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Source: Bunker Hill Mining

Harte-Hanks Inc. (HRTH) – Raising Price Target Shifting More Attention Toward Growth

Posted on by Admin

Thursday, April 01, 2021

Harte-Hanks Inc. (HRTH)
Raising Price Target; Shifting More Attention Toward Growth

Harte-Hanks is a marketing services company that provides multichannel marketing solutions as well as consulting, data analytics, and strategic assessment. The company’s offerings focus on business-to-business, retail, finance, and automotive segments through digital, social, mobile, and print media offerings. Harte-Hanks strives to develop better customer relationships through its marketing and analytical services for clients. The majority of its revenue is derived from its marketing services in the retail, technology, and consumer brand segments.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Increased transparency. The company filed its 10K last week with segment results by quarter for 2019 and 2020. We believe that the segment data provides greater operating transparency. In this report, we provide our segment forecasts and our quarterly and full year 2021 estimates, as well as our full year 2022 estimates.

    Refining Q1 estimates.  Q1 ’21 is expected to reflect total company revenue growth, the first time since 2014, on the heals of a strong performance in its Customer Care segment. While revenue growth is not expected to be sustainable in the following 2021 quarters, it illustrates that the company is on the cusp of improved revenues and cash flow performance. Importantly, Q1 cash flow, as measured by …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.